All research
LL-37 2026-07-14 PubMed

HBV pgRNA drives chronic inflammation in CHB patients by inducing IL-1β in neutrophils

HBV pgRNA induces chronic inflammation in an IL-1β-dependent manner.

Background

Despite advancements in antiviral therapies like nucleoside analogs (NAs), Chronic Hepatitis B (CHB) remains a significant global health burden, often progressing to cirrhosis and hepatocellular carcinoma. A key gap in understanding CHB pathogenesis is the role of viral components beyond canonical proteins in driving chronic inflammation. While HBV pregenomic RNA (pgRNA) is known as a marker of viral transcriptional activity, its direct involvement in modulating innate immunity and contributing to the persistent inflammatory state in CHB patients has been poorly understood, representing a critical area for investigation to identify novel therapeutic targets.

Study Design

Researchers enrolled a cohort of 88 patients with CHB who were receiving nucleoside analogs (NAs). For a deeper mechanistic dive, samples from 8 HBeAg-negative CHB patients (4 positive for HBV pgRNA, 4 negative) underwent transcriptomic analysis. Bioinformatic tools identified common pathways, leading to experimental setups investigating platelet activation and platelet-neutrophil interactions. The study also examined the synthesis and expression of key inflammatory interleukins, specifically IL-1β, IL-17A, and the antimicrobial peptide LL-37, to elucidate the innate immune response triggered by HBV pgRNA.

Results

HBV pgRNA was detected in 18.1% of the total study population. Transcriptomic analysis of pgRNA-positive versus pgRNA-negative patients revealed common differentially expressed genes primarily involved in platelet activation and neutrophil degranulation pathways. Further experimental validation showed that platelets stimulated with HBV pgRNA-positive serum exhibited induced autophagy and de novo synthesis of the peptide LL-37. Crucially, a combined study of platelet-neutrophil interactions demonstrated a pronounced proinflammatory phenotype, characterized by significantly high levels of IL-1β in neutrophils, which was accompanied by minimal NET formation. This suggests a specific, IL-1β-dependent inflammatory axis.

Platelets stimulated with HBV pgRNA-positive serum showed induction of autophagy and de novo synthesis of the peptide LL-37, indicating a direct role for pgRNA in cellular responses.

Key Findings

  • HBV pgRNA was detected in 18.1% of CHB patients receiving nucleoside analogs.
  • Transcriptomic analysis identified platelet activation and neutrophil degranulation pathways in pgRNA-positive patients.
  • HBV pgRNA-positive serum induced autophagy and LL-37 synthesis in platelets.
  • Platelet-neutrophil interactions with pgRNA-positive serum led to high IL-1β levels in neutrophils.
  • A proinflammatory phenotype was observed, characterized by IL-1β induction and minimal NET formation.

Why It Matters

This research significantly advances our understanding of CHB pathogenesis, highlighting HBV pgRNA as a direct driver of inflammation, rather than just a viral activity marker. For clinicians, this suggests that monitoring pgRNA levels could serve as a prognostic indicator for inflammatory burden, even in patients on NAs. It opens avenues for developing adjunctive anti-inflammatory therapies targeting IL-1β or platelet activation pathways, potentially improving outcomes beyond current antiviral strategies. Identifying pgRNA's role in innate immunity provides a novel therapeutic target to mitigate chronic inflammation in CHB, moving towards more personalized and comprehensive treatment approaches for patients who continue to experience inflammation despite viral suppression.


hbv chronic-hepatitis-b inflammation il-1beta ll-37 innate-immunity
Source: pubmed:42440489 · Ingested 2026-07-14 · Digest: gemini-2.5-flash